Hua Xia Shi Bao·2025-08-08 04:52Group 1 - The core viewpoint of the article highlights the recent surge in stock prices of Anchek Testing and the comparison with the previous case of Shangwei New Materials, indicating that such dramatic price movements may not be easily replicated in the future [1][2][6] - Shangwei New Materials experienced a 15-fold increase in stock price due to the asset injection from Zhiyuan Robotics, while Anchek Testing's stock rose significantly after announcing a similar asset injection from Shanghai Xirui Technology [1][2] - An analysis of the market sentiment suggests that the excitement around reverse asset injections is high, but the risks associated with such investments are substantial, particularly given the differences in shareholder structures and asset values between the two companies [2][7] Group 2 - Shanghai Xirui Technology, established in 2012, focuses on the smart sensor field and has been preparing for an IPO for several years, indicating its strategic positioning in high-growth sectors [3][5] - The asset injection agreement involves a phased approach, with the first phase including the acquisition of 14.72 million shares at a price of 21.84 yuan per share, totaling approximately 322 million yuan [8] - The financial performance of Anchek Testing has been concerning, with continuous losses reported from 2022 to the first quarter of 2025, raising questions about the sustainability of its business model [5][9]